SCHEMBL25821367

SCHEMBL25821367

N#C[C@@]1(c2cc(F)c3c(N)ncnn23)O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@H]1O

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ACVRL1 P37023 14/20 0.34
▸ POLRMT O00411 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819188 0.84 POLRMT (0.42) POLRMT
SCHEMBL23922551 0.84 POLRMT (0.42) POLRMT
SCHEMBL25821386 0.84 ACVRL1 (0.35) ACVRL1
SCHEMBL23959975 0.81 ACVRL1 (0.38) ACVRL1
SCHEMBL25821369 0.81 ACVRL1 (0.39) ACVRL1
SCHEMBL25821372 0.80 ACVRL1 (0.37) ACVRL1
SCHEMBL25821376 0.79 ACVRL1 (0.36) ACVRL1
SCHEMBL20819189 0.76 POLRMT (0.41) POLRMT
SCHEMBL23959993 0.76 POLRMT (0.48) ACVRL1POLRMT
SCHEMBL20756371 0.75 POLRMT (0.40) ACVRL1POLRMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG VIGONVITA LIFE SCIENCES CO., LTD. (CN) 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG PNP, TYMP, PIGS ACVRL1 712/4885POLRMT 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback